Demand for desalting and buffer exchange is expanding as more industries want easier purification. This is primarily due to rising service demand.
Since biologic therapies will need more advanced purification technologies to ensure quality and safety, the biopharmaceutical sector is a major player in this market. Desalting and buffer exchange were essential to achieving these aims.
Increasing technology in buffer exchange and desalting procedures is boosting the market's growth. Due to membrane technology and chromatography advances, purification operations are becoming faster and more efficient.
Due to global water crisis concerns, desalination technologies are driving the industry. This development is also driving desalination. Desalination is becoming a viable option that boosts market trends. This is done to find sustainable water sources.
Market research and development programs to improve desalting and buffer exchange technologies have increased. This initiative is market-driven. This is leading to more effective and cost-efficient solutions, which is increasing investment and market share.
Outsourcing pharmaceutical manufacture is also affecting desalting and buffer exchange. This tendency affects the firm. Contract manufacturing organizations (CMOs) are using complex purifying methods to meet customer needs, which is growing the industry.
Desalting and buffer exchange are pharmaceutical and biopharmaceutical technologies that are growing. The strict regulations that regulate these enterprises cause this. Manufacturers ensure their market impact by investing in quality solutions. This ensures a positive influence.
Due to biopharmaceutical sector growth and bioprocessing facility capacity, desalting and buffer exchange technologies are needed. The main cause of this demand is bioprocessing plant capacity growth. These steps ensure bioproduct integrity when used in big quantities.
The industries are focusing on cost-effective purification procedures. The simpler methods of desalting and buffer exchange provide financial benefits. Thus, these technologies provide tempting potential for industrial process improvement.
As nations with water shortages adopt desalting and buffer exchange technology, the worldwide market for these technologies is growing. Because developed and emerging countries are realizing the value of these technologies, market growth is accelerating worldwide.
Desalting and buffer exchange technology is growing as companies realize the significance of environmental sustainability. These techniques' qualities cause their environmental advantages. Due of this trend, more firms are choosing purifying systems that meet their environmental goals.
Despite optimistic trends, broad adoption is hindered by factors including the requirement for competent system managers and high initial expenditures. To expand the industry, these obstacles must be overcome.
The Desalting and Buffer Exchange Market is projected to reach USD 1.4 Billion by 2032 at 10.2% CAGR during the forecast period 2023-2032. Desalting is a method for separating soluble low molecular weight compounds from nucleic acid and protein samples. Buffer exchange, on the other hand, is the process of replacing one set of buffer salts with another.
In May 2024, the oligonucleotides market is experiencing significant growth, as drug developers are becoming more interested in this fascinating medicinal modality. However, the process of production can be difficult, and it is crucial to select the appropriate machinery for the task. Experienced suppliers, like Asahi Kasei Bioprocess (AKB), may offer valuable advice on choosing equipment for your process and assist in optimizing the production of these intricate therapies. Oligonucleotide therapies exhibit exceptional efficacy and remarkable selectivity. They possess the ability to specifically target the specific location where they exert their effects, such as the control of gene expression. This characteristic makes them highly promising for the treatment of metabolic illnesses, genetic diseases, and cancer, as well as for the prevention of infectious diseases. In recent years, there has been rapid progress in the research, production, and commercialization of oligonucleotides, leading to significant growth in the global market.
In April 2020, Pall Corporation, a worldwide frontrunner in filtration, separation, and purification, unveiled the latest iteration of their laboratory-scale tangential flow filtration (TFF) products. The Minimate EVO TFF system offers superior efficiency, consistency, and ease of control in comparison to stirred-cell technologies. The user-friendly technology streamlines laboratory-scale processes for concentration, desalination, and buffer exchange workflows. The Minimate system developed by Pall is specifically designed for the efficient and dependable exchange of buffers or concentration of proteins in samples of up to one liter.
The Minimate TFF system demonstrated a five-fold increase in the speed of concentrating a one-liter protein solution compared to a similar stirred-cell system, as observed in tests. This result was verified by an independent researcher during the purification of the cyclooxygenase-2 enzyme, leading to a reduction in processing time by over three times without compromising protein activity. The Minimate EVO system has enhanced the first-generation Minimate by incorporating integrated upstream and downstream pressure gauges to accurately calculate transmembrane pressure (TMP) differentials. This enables enhanced user control and simplified validation. Furthermore, the Minimate EVO has enhanced agitation, sturdier tubing and connectors, and a generally simplified setup and operation.
Furthermore, buffer exchange is an important step in the processing of biological samples, since it prepares the material for downstream uses. In recent years, the worldwide desalting and buffer exchange sector have seen tremendous expansion. Furthermore, factors such as increased research and development investment by major biopharmaceutical firms, as well as a growing focus on proteomic and genomic research, are expected to support market growth throughout the forecast period.
The Desalting and Buffer Exchange Market has been segmented into technique, product, and application. On the basis of technique, the market has been segmented into filtration, chromatography, and precipitation. The filtration segment has been further segmented into ultrafiltration and dialysis. The chromatography segment has been segmented into size-exclusion chromatography and others.
The market, by product, has been segmented into kits, cassettes, filter plates, spin columns, membrane filters, and others.
The market, by application, has been segmented into bioprocess applications and diagnostic applications. The bioprocess segment is expected to account for the largest market share in 2017. The market growth of the segment is attributed to the increasing demand for biopharmaceutical products.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The desalting and buffer exchange market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European desalting and buffer exchange market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The desalting and buffer exchange market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The desalting and buffer exchange market in the Middle East & Africa has been segmented into the Middle East and Africa.
Some of the key players in the desalting and buffer exchange market are:
Geographically, the Americas is anticipated to dominate the desalting and buffer exchange market owing to the rising demand for biopharmaceuticals, rising R&D expenditure by biopharmaceutical companies, and increasing research activities in the field of genomics and proteomics.
Europe is expected to hold the second largest position in the desalting and buffer exchange market. The market growth in this region is attributed to the increasing number of research and development activities in the region.
The desalting and buffer exchange market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the continuously growing biotechnology sector and increasing regional expansion by prominent market players.
The Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.
Recent Development
November 2023: Cytiva announces the launch of its new ÄKTA go Desalting and Buffer Exchange System. The system is designed to automate desalting and buffer exchange workflows, making them faster, more efficient, and more reproducible. Thermo Fisher Scientific announces the launch of its new Pierce™ Desalting and Buffer Exchange Columns. The columns are designed to provide fast and efficient desalting and buffer exchange for proteins and other biomolecules. Merck announces the launch of its new LiChrosolv® Buffer Exchange Buffers. The buffers are designed to be compatible with a variety of desalting and buffer exchange techniques, including chromatography, dialysis, and filtration.Agilent Technologies, Inc. (Agilent or 'the firm') provides equipment, software, services, and consumables that enable clients in the clinical and life sciences research fields to identify, analyze, and measure the biological and physical characteristics of substances and products. Pharmaceutical and biopharmaceutical companies, academia and government, chemical and energy companies, environmental and forensics companies, diagnostics and clinical companies, and food companies all use the company's services. California is the company's headquarters.
PhyNexus, Inc., a privately owned California firm, said today that it has agreed to be purchased by Biotage AB (Nasdaq Stockholm: BIOT.ST), enhancing its position in the global sales and marketing of automated lab-scale biomolecule purification technology. PhyNexus and Biotage will be able to provide its worldwide clients a platform based on Dual Flow Chromatography and unique tip technology for high throughput purification of biomolecules such as proteins, plasmids, and antibodies at the lab scale.
Desalting and Buffer Exchange Market, by Technique
Desalting and Buffer Exchange Market, by Product
Desalting and Buffer Exchange Market, by Application
Desalting and Buffer Exchange Market, by Region
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)